Interaction of cyclosporin A with antilymphocyte serum and with enhancing serum for the suppression of renal allograft rejection in the rat.
The interactions between antilymphocyte serum (ALS) and cyclosporin A and between enhancing serum cyclosporin A were investigated in a DA to Lewis rat renal allograft model. Subtherapeutic doses of cyclosporin A (2 mg/kg/day), when combined with enhancing serum, produced no consistently beneficial effect in animal survival. A short course of cyclosporin A in therapeutic doses (5 mg/kg/day for 4 days) with enhancing serum was also no better than either agent used alone in prolonging rat survival. Subtherapeutic doses of ALS along with subtherapeutic doses of cyclosporin A (2 mg/kg/day) showed a favorable interaction, prolonging animal survival to a median of 59 days. Combination of immunosuppressive agents did not improve the histological picture of allograft rejection when compared to that seen when the agents were used individually. That cyclosporin A plus ALS show a favorable interaction, whereas cyclosporin A plus enhancing serum does not, may indicate that cyclosporin A and enhancing serum operate on the same portion of the immune response.
D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003524:Cyclosporins; D004306:Dose-Response Relationship, Immunologic; D004347:Drug Interactions; D004357:Drug Synergism; D006082:Graft Enhancement, Immunologic; D006084:Graft Rejection / Q000187:drug effects; D007106:Immune Sera / Q000494:pharmacology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents; D016030:Kidney Transplantation; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D007106:Immune Sera; D007166:Immunosuppressive Agents; D010456:Peptides, Cyclic